Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated G-CSF prophylaxis for neutropenia in patients with metastatic triple-negative breast cancer receiving sacituzumab govitecan
KCT0010019Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in triple-negative breast cancer (TNBC), sponsored by Samsung Medical Center. Primary endpoint: Incidence of neutropenia. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0010019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010019.